FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1964807225> ?p ?o ?g. }

• W1964807225 endingPage "85" @default.
• W1964807225 startingPage "79" @default.
• W1964807225 abstract "Small cell lung cancer (SCLC) is a chemoresponsive tumor but overall survival remains poor even in limited disease (LD). With the aim of eradicating chemoresistant tumor cells and reducing toxicity, we investigated in this phase II trial the feasibility and outcome of a sequential approach of induction chemotherapy (CT) followed, in responding patients with LD-SCLC, by intensified platinum-based CT and concurrent thoracic irradiation (TI).We treated 55 consecutive LD-SCLC patients with three 21-day cycles of cyclophosphamide, epiadriamycin and vincristine (CEV) as induction CT. In 44 (80%) patients there was an objective response and they received treatment intensification consisting of TI and concomitant CT with carboplatin and etoposide plus recombinant granulocite colony stimulating factor. Twenty-five (57%) patients were submitted to twice-daily thoracic irradiation (TDTI; 1.5 Gy per fraction, to a total dose of 45 Gy) and 19 (43%) to once-daily thoracic irradiation (ODTI; 2 Gy per fraction, to a total dose of 50 Gy).Median follow up was 75 months (range, 42-102). Of 44 patients submitted to intensification with TI plus CT, 32 (73%) had a complete and 12 (27%) a partial response. Median overall survival of all 55 patients was 17 months with actuarial survival probabilities of 2 and 5 years, 32 and 25%, respectively. Analysis of patient sub-groups showed a 5-month median survival in non-responders, 19 in TDTI and 17 in ODTI patients, respectively. Two and 5 year survival probabilities were 0% in non-responders, 40 and 35% in TDTI and 39 and 21% in ODTI patients, respectively. At present, 13 of 44 responders are still alive, of which nine (20%) have been progression-free from 45 to 93 months (median 60). Treatment failure was registered in 31 (70%) of 44 patients who received both induction and intensification treatment. One-half of patients had intrathoracic recurrence, eight of which only local and the remaining seven local and distant. Fourteen (32%) patients had brain metastases. Grade 3-4 neutropenia occurred in 24 (55%) patients with no differences between treatment groups. Grade 3 esophagitis was registered in four (9%) patients: in 3/25 (12%) and 1/19 (5%) of those who received TDTI and ODTI, respectively (P=not significant). Acute radiation pneumonitis occurred in three (12%) patients submitted to TDTI. No clinically debilitating pulmonary fibrosis, permanent esophageal stricture or toxic death was observed.In LD-SCLC patients late concurrent CT plus TI is feasible and effective. Our long-term results are similar to the best reported in the literature. Despite the high incidence of complete response obtained, however, one-half of the patients had intrathoracic relapse and one-third brain metastases." @default.
• W1964807225 created "2016-06-24" @default.
• W1964807225 creator A5001259661 @default.
• W1964807225 creator A5003664573 @default.
• W1964807225 creator A5008403882 @default.
• W1964807225 creator A5012875014 @default.
• W1964807225 creator A5013396009 @default.
• W1964807225 creator A5026459926 @default.
• W1964807225 creator A5030661498 @default.
• W1964807225 creator A5037878656 @default.
• W1964807225 creator A5061095811 @default.
• W1964807225 creator A5062180939 @default.
• W1964807225 creator A5079039762 @default.
• W1964807225 creator A5087174289 @default.
• W1964807225 date "2002-07-01" @default.
• W1964807225 modified "2023-10-16" @default.
• W1964807225 title "Long-term results of induction chemotherapy followed by concurrent chemotherapy and thoracic irradiation in limited small cell lung cancer" @default.
• W1964807225 cites W1884032213 @default.
• W1964807225 cites W1885320430 @default.
• W1964807225 cites W1898381946 @default.
• W1964807225 cites W1898563448 @default.
• W1964807225 cites W1900393559 @default.
• W1964807225 cites W1918962731 @default.
• W1964807225 cites W1935482218 @default.
• W1964807225 cites W1961171505 @default.
• W1964807225 cites W1961685780 @default.
• W1964807225 cites W1969034942 @default.
• W1964807225 cites W1986382059 @default.
• W1964807225 cites W2005412601 @default.
• W1964807225 cites W2048771412 @default.
• W1964807225 cites W2049247217 @default.
• W1964807225 cites W2073153700 @default.
• W1964807225 cites W2083817990 @default.
• W1964807225 cites W2088766047 @default.
• W1964807225 cites W2097856715 @default.
• W1964807225 cites W2124353451 @default.
• W1964807225 cites W2128175002 @default.
• W1964807225 cites W2173643829 @default.
• W1964807225 cites W2247198812 @default.
• W1964807225 cites W2256738179 @default.
• W1964807225 cites W2263690797 @default.
• W1964807225 cites W2287470414 @default.
• W1964807225 cites W2323020638 @default.
• W1964807225 cites W2339444986 @default.
• W1964807225 cites W2341227544 @default.
• W1964807225 cites W2341745217 @default.
• W1964807225 doi "https://doi.org/10.1016/s0169-5002(02)00028-4" @default.
• W1964807225 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12057871" @default.
• W1964807225 hasPublicationYear "2002" @default.
• W1964807225 type Work @default.
• W1964807225 sameAs 1964807225 @default.
• W1964807225 citedByCount "11" @default.
• W1964807225 countsByYear W19648072252015 @default.
• W1964807225 countsByYear W19648072252016 @default.
• W1964807225 countsByYear W19648072252023 @default.
• W1964807225 crossrefType "journal-article" @default.
• W1964807225 hasAuthorship W1964807225A5001259661 @default.
• W1964807225 hasAuthorship W1964807225A5003664573 @default.
• W1964807225 hasAuthorship W1964807225A5008403882 @default.
• W1964807225 hasAuthorship W1964807225A5012875014 @default.
• W1964807225 hasAuthorship W1964807225A5013396009 @default.
• W1964807225 hasAuthorship W1964807225A5026459926 @default.
• W1964807225 hasAuthorship W1964807225A5030661498 @default.
• W1964807225 hasAuthorship W1964807225A5037878656 @default.
• W1964807225 hasAuthorship W1964807225A5061095811 @default.
• W1964807225 hasAuthorship W1964807225A5062180939 @default.
• W1964807225 hasAuthorship W1964807225A5079039762 @default.
• W1964807225 hasAuthorship W1964807225A5087174289 @default.
• W1964807225 hasConcept C126322002 @default.
• W1964807225 hasConcept C126894567 @default.
• W1964807225 hasConcept C141071460 @default.
• W1964807225 hasConcept C2776256026 @default.
• W1964807225 hasConcept C2776611710 @default.
• W1964807225 hasConcept C2776694085 @default.
• W1964807225 hasConcept C2776755627 @default.
• W1964807225 hasConcept C2778119113 @default.
• W1964807225 hasConcept C2778239845 @default.
• W1964807225 hasConcept C2779384505 @default.
• W1964807225 hasConcept C2779429289 @default.
• W1964807225 hasConcept C2779562246 @default.
• W1964807225 hasConcept C2781451048 @default.
• W1964807225 hasConcept C2989005 @default.
• W1964807225 hasConcept C45393284 @default.
• W1964807225 hasConcept C500558357 @default.
• W1964807225 hasConcept C509974204 @default.
• W1964807225 hasConcept C71924100 @default.
• W1964807225 hasConcept C90924648 @default.
• W1964807225 hasConceptScore W1964807225C126322002 @default.
• W1964807225 hasConceptScore W1964807225C126894567 @default.
• W1964807225 hasConceptScore W1964807225C141071460 @default.
• W1964807225 hasConceptScore W1964807225C2776256026 @default.
• W1964807225 hasConceptScore W1964807225C2776611710 @default.
• W1964807225 hasConceptScore W1964807225C2776694085 @default.
• W1964807225 hasConceptScore W1964807225C2776755627 @default.
• W1964807225 hasConceptScore W1964807225C2778119113 @default.
• W1964807225 hasConceptScore W1964807225C2778239845 @default.
• W1964807225 hasConceptScore W1964807225C2779384505 @default.
• W1964807225 hasConceptScore W1964807225C2779429289 @default.

• next